CervoMed Inc. Announces UK Innovation Passport for Neflamapimod

What Happened

• On August 4, 2026, CervoMed Inc. (CRVO) filed a Form 8‑K (Items 7.01 and 8.01) to disclose a press release announcing that neflamapimod has been granted an Innovation Passport to enter the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in dementia with Lewy bodies.
• The press release is attached to the filing as Exhibit 99.1 and certain paragraphs of that release are incorporated by reference into the Form 8‑K.

Key Details

• Date of disclosure: August 4, 2026 (press release and Form 8‑K filing).
• Drug: neflamapimod; Indication: dementia with Lewy bodies (DLB).
• Designation: Granted an Innovation Passport to enter the UK Innovative Licensing and Access Pathway (ILAP).
• Filing items: Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events); Exhibit 99.1 is the press release.

Why It Matters

• The filing reports a regulatory milestone for CervoMed’s DLB program: the Innovation Passport places neflamapimod into the UK ILAP process, a formal route referenced in the company’s public disclosure.
• For investors, this is an update on the company’s development and regulatory engagement in the UK market. The filing does not report financial results, operational changes, or other corporate actions.